Molbio raised R&D spending 46% to advance three platforms
Key highlights
- Molbio spent Rs 87.5 crore on R&D in FY26, 46% above Rs 59.8 crore in FY24.
- Molbio’s R&D pipeline identifies Trueamp, Truepoc and Truecyte as three new platforms.
- Molbio sold 17.56 million Truenat test kits in FY26, compared with 8.8 million in FY24.
- Molbio disclosed 34 human assays across 22 diseases and seven veterinary assays in its pipeline.
powered by IRIS

Molbio raised annual research and development (R&D) spending to Rs 87.5 crore in financial year FY26, 46% above Rs 59.8 crore in FY24, while disclosing three new diagnostic platforms: Trueamp, Truepoc and Truecyte. The programme extends beyond the Truenat molecular-testing platform and includes new assays, point-of-care technologies and digital pathology.
Know Molbio Diagnostics inside out
Results, valuation, peers and who's buying, in one view.
Why did Molbio increase R&D spending?
Molbio increased R&D spending to support future platforms, assays and revenue streams. Annual expenditure rose from Rs 59.8 crore in FY24 to Rs 68.6 crore in FY25, an increase of 15%, and then to Rs 87.5 crore in FY26, a further 28% rise. Cumulative R&D investment over FY24 to FY26 was Rs 215.8 crore.
Molbio reported 153 R&D professionals, including 136 scientists, and 207 patents granted in India and overseas. Its work spans biology, chemistry, software, engineering, product development, evidence generation and scale-up, while its Bengaluru R&D facility is recognised by the Department of Scientific and Industrial Research.
How is Molbio developing new diagnostic platforms?
Molbio is developing Trueamp, Truepoc and Truecyte for different testing settings and applications. Trueamp Mini is a portable analyser designed for custom-panel testing with up to 16 targets in each run. The stated design broadens the platform focus from individual disease assays towards custom diagnostic panels.
Truepoc is a fully integrated, one-step, near point-of-care molecular diagnostics platform intended to detect tuberculosis in sputum swabs and tongue swabs. This differs from the central-laboratory model, where samples are transported for testing and turnaround can take hours or days. Molbio’s existing Truenat platform provides results in about 60 minutes.
Truecyte is an artificial intelligence-powered digital pathology system designed to provide rapid peripheral blood smear-based diagnostics at the point of care for human and veterinary use. The platform is part of a broader pathology effort that includes Molbio’s 2024 strategic investment in OptraSCAN and its 2026 collaboration with Equine Biotech for veterinary diagnostics development.
What existing business supports Molbio’s R&D expansion?
Molbio has sold more than 12,500 Truenat devices globally, including an estimated India installed base of about 8,000 to 10,000 devices. The Truenat menu comprises 43 assays across 30 diseases, including tuberculosis, hepatitis B and C, human immunodeficiency virus, human papillomavirus, COVID-19, dengue and influenza.
Truenat test-kit volumes increased from 8.8 million units in FY24 to 12.24 million in FY25 and 17.56 million in FY26, which Molbio presents as about 41% compound annual growth for FY24 to FY26. Test kits accounted for 67.78% of product revenue in FY24, 74.31% in FY25 and 73.98% in FY26, showing that consumables remained the largest product-revenue component despite a small increase in the device share during FY26.
Molbio operates six manufacturing facilities across Goa, Visakhapatnam, Bengaluru and Pune. These facilities have annual capacity for 39 million Truenat test kits and 5,400 Truenat devices, with FY26 utilisation of 58.25% for kits and 42.30% for devices. The company manufactures core products in-house and uses electronics manufacturing services partners for Truenat device assembly.
Got a follow-up? Ask IRIS
What assays and markets does Molbio plan to add?
Molbio disclosed a pipeline of 34 human assays spanning 22 diseases, alongside one rabies assay and six additional veterinary assays. The pipeline covers communicable and non-communicable diseases. New Truenat assays can increase the utility of installed devices because disease-specific, single-use kits are designed exclusively for the Truenat platform.
Molbio also says it plans to develop new point-of-care platforms using advanced multiplex polymerase chain reaction technologies. The named diagnostic areas are immunochemistry, hematology, histopathology, biochemistry and antimicrobial resistance. The presentation does not disclose spending allocations, clinical-validation schedules, launch dates or revenue targets for individual platforms.
The company is focused on enhancing exports in Africa and Southeast Asia, where it already has a presence, and plans to enter the European Union and US with its portfolio. Revenue from outside India rose to 19% of H1 FY27 revenue from operations from 8% in H1 FY26, while India’s share declined to 81% from 92%. Total revenue from operations was Rs 667 crore in H1 FY27, compared with Rs 680 crore in H1 FY26.
How do radiology and digital pathology fit Molbio’s strategy?
Molbio expanded into radiology through its 2023 acquisition of Prognosys Medical Systems Private Limited and into digital pathology through its 2024 strategic investment in OptraSCAN. Prognosys offers PRORAD X-ray screening for tuberculosis, which Molbio presents alongside Truenat reverse-transcription polymerase chain reaction confirmatory testing. Prognosys received US Food and Drug Administration 510(k) clearance for Prorad Atlas Ultraportable products in 2025 and European Union Medical Device Regulation certification for PRORAD systems in 2026.
OptraSCAN’s portfolio ranges from the six-slide OS-SiX Brightfield Scanner to OS-Ultra systems that handle 80 to 480 slides. Molbio says certain OS-Ultra models scan slides in under 60 seconds and that the offering combines scanners, AI-powered analysis tools and telepathology services. OptraSCAN received US Food and Drug Administration 510(k) clearance for its OptraScan System in 2026, alongside Molbio’s disclosed Truecyte development.
Conclusion
Molbio’s Rs 87.5 crore FY26 R&D expenditure links its established Truenat business with a wider diagnostic portfolio. The company is combining more than 12,500 Truenat devices sold, 17.56 million FY26 test kits sold and 43 assays across 30 diseases with development of Trueamp, Truepoc and Truecyte, plus radiology and digital pathology operations.
The next disclosed items to watch are the pipeline of 34 human assays across 22 diseases, one rabies assay and six veterinary assays, as well as planned entry into the European Union and US. Molbio has stated platform functions and intended uses for Trueamp, Truepoc and Truecyte, but has not disclosed commercialisation dates, validation schedules or platform-level revenue targets.


